Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5440_Библиотеки_им_академика_М_И_Перельмана.pdf
313
concentration of substrate induces the inhibitor to be shifted away from the active site. By inte-
grating the substrate and elevating its concentration to exceed that of the inhibitor, competitive
inhibition can be utterly reversed. Reversible inhibition studies have shed light on unique
enzyme–substrate complexes and the interactions involving different entities at the active site. As
a result, pharmaceutical companies have developed medications that suppress unique cancer
cells and bacteria’s metabolic activities through competition. Numerous medications are com-
petitive inhibitors of particular enzymes [14].
14.3.2 Irreversible Inhibitors
By forging an irreversible covalent link with a specific group at the active site, an inhibitor
inactivates an enzyme. Because of how strongly the inhibitor adheres to the enzyme, too much
substrate will not make the inhibition disappear. By generating an enzyme–inhibitor tandem
with a particular OH group of serine prevalent at the active sites of several enzymes, the nerve
gases, particularly diisopropyl fluorophosphates (DIFP), irreversibly impede biological sys-
tems. DIFP suppresses trypsin and chymotrypsin, both of which have serine groups at their
active sites [14].
14.3.3 Competitive Inhibitors
In the context of competitive inhibition, the inhibitor and the substrate strive to bind to the
enzyme’s active site. The substrate and this sort of inhibitor are structurally associated. The inabil-
ity to adhere to the substrate implies diminished enzyme activity [15] (Figure 14.1).
14.3.4 Noncompetitive Inhibitors
By adhering to the enzyme at a location other than the active site, noncompetitive inhibition pre-
cludes the enzyme from executing the catalyzed reaction as envisaged. An alteration, typically
conformational, which ensues from the inhibitor’s adherence to the enzyme might hinder the
enzyme from binding the substrate or from functioning on a substrate that has already been bound.
In any situation, boosting the substrate’s availability will not be able to completely counteract the
inhibitor’s consequences [15].
Enzyme
Drug
SubstrateSubstrate
Drug
Active site
Enzyme
Figure 14.1 Competitive inhibition of the enzyme.
314
14.3.5 Allosteric Modulators
The secondary binding site implications are the core of an unusual approach to drug design. Small
molecule medications are generated in this method to bind onto secondary binding sites on the
targeted biomolecules rather than the major orthosteric sites. Allosterism is the term adopted to
refer to the strategy and its secondary locations. A successful allosteric modulator will have the
ability to attach to an allosteric site and remotely alter the conformation of the biological target’s
dominant orthosteric binding site [16].
The orthosteric positioning of the enzyme or receptor protein may be impacted by this confor-
mational alteration in the following ways [17]:
● The allosteric alteration may elevate the ligand’s binding affinity to the orthosteric site, enhanc-
ing the signal or boosting activity. Positive allosteric modulators are the substances that exhibit
these effects.
● The orthosteric binding site may become retarded or repressed as a result of the allosteric modu-
lation, which will attenuate the signal or diminish activity. Negative allosteric modulators are
the substances that generate this result.
14.4 Strategies Employed in the Design and Development
of Enzyme Inhibitors
14.4.1 Structure-Based Design
Structure-based drug design is one of the most crucial methods to generate enzyme inhibitors. This
strategy utilizes the target enzyme’s three-dimensional structure to pinpoint possible binding sites
and generate inhibitors that perfectly complement the active site. Researchers can create inhibitor
compounds that are optimized to effectively impede enzymatic activity by comprehending the con-
nections involving the enzyme and its substrate. Pharmaceutical research and development focus
a high priority on comprehending the mechanisms by which small-molecule ligands recognize
and interact with macromolecules [18]. Structure-based design is the methodical implementation
of structural data, either acquired experimentally or through computer homology modeling, such
as macromolecular targets, referred to as receptors [19].
To obtain high receptor binding affinity, the intention is to generate ligands that possess par-
ticular electrostatic and stereochemical attributes. An in-depth investigation of the binding site
design is conceivable because of the accessibility of three-dimensional macromolecular struc-
tures. Precise investigation of electrostatic attributes is also accessible. Current techniques
facilitate the fabrication of ligands with the attributes needed for effective regulation of the
target receptor [20]. High-affinity ligands precisely modulate a validated drug target, compet-
ing with particular cellular processes to provide the envisioned pharmacological and therapeu-
tic outcomes [21]. To find conceivable ligands, in silico investigations are carried out starting
with a known target structure. The most intriguing molecules are synthesized after these
molecular modeling approaches. Then, utilizing an array of experimental platforms, assess-
ments of biological parameters such as effectiveness, affinity, and efficacy are conducted [22].
The three-dimensional structure of the ligand-receptor complex can be resolved, provided that
active substances are identified. Because of the available structure, it is feasible to discern an
array of intermolecular attributes that assist in molecular recognition. The analysis of binding
conformations, the characterization of substantial intermolecular interactions, the definition
315
of speculative binding sites, mechanistic studies, and the clarification of ligand-induced con-
formational alterations are all made possible by structural descriptions of ligand–receptor com-
plexes [23]. Following the recognition of a ligand–receptor complex, biological activity data
corresponds with the structural details. In this fashion, the approach resumes with new phases
that incorporate molecular alterations that can boost the affinity of fresh ligands for the binding
site [24] (Figure 14.2).
14.4.2 Computer-Aided Design
The domain of computer-aided design integrates an array of chemical-molecular and quantum
strategies with the intention of identifying, developing, and generating therapeutic chemical
agents. The discovery process was facilitated by the implementation of an amalgamation of
leading-edge computer strategies, biological investigation, and synthesis of chemicals, and this
combinational circuitry approach broadened the scope of discovery. The acronym computer-
aided design came to be employed to denote the implementation of computers in developing
drugs [25]. Major accomplishments have been made leveraging these techniques, which have
shown to be beneficial resources for advanced computational applications. In the specialized field
of CADD, many computational techniques are utilized to model interactions between receptors
and medicines to ascertain binding affinities [26]. The method has numerous additional applica-
tions besides analyzing chemical interactions and projecting binding affinities, such as generat-
ing compounds with specific physiochemical attributes and managing digital archives of
chemicals (Figure 14.3).
Molecular
target
Complex formed by
ligand and receptor
Molecular modeling
Design of new ligand
Figure 14.2 Strategies involved in structure-based design.
316
14.4.3 Fragment-Based Design
In the development of enzyme inhibitors, fragment-based drug design is another viable method. In
this technique, minuscule enzyme-binding molecule fragments are first expanded and improved
to generate formidable inhibitors. Researchers can explore an expanded chemical space and
uncover new inhibitors that have substantial intensity and selectivity by commencing with smaller,
structurally varied fragments. Modifying the arrangement of substrates and cofactors, or emulat-
ing intermediates or phases of transition in the postulated reaction mechanism, are prominent
strategies applied to the logical development of enzyme inhibitors. When this is inadequate as an
initial point to start, inhibitors are frequently found by analyzing libraries of thousands of
chemicals [27].
Four stages comprise a fragment-based strategy for inhibitor design: (i) designing and assem-
bling fragment libraries; (ii) screening fragments against a compatible variant of the target enzyme;
(iii) assessing the hits; and (iv) upgrading fragments into improved inhibitors. The procedure
entails qualitatively selecting segments that interact with the target protein, verifying and analyz-
ing this interaction to precisely pinpoint the fragment while outlining its binding mode, and then
iteratively upgrading the fragment into a more effective, substantial inhibitor [28] (Figure 14.4).
14.4.4 Virtual Screening Method
Presently, a crucial step in the process of medication discovery and design is virtual screening (VS).
VS is typically thought of as the selection of promising therapeutic candidates utilizing computa-
tional approaches from massive libraries of chemical structures [29].
14.4.4.1 Ligand Based
Using known ligands or substrates for an enzyme as a base for ligand-based drug design is an alter-
native approach. Inhibitors with comparable attributes can be generated by analyzing the struc-
ture and attributes of these compounds. The goal of ligand-based approaches is to locate achievable
inhibitors that interact well with the enzyme through the use of computational techniques of
VS. Based on the presumption that similar compounds have similar effects, ligand-based VS tech-
niques look for molecules that possess certain relevant common properties with known binding
chemicals [30]. One or more substances that are known to adhere to the biological target of
Computer-
aided design
Identification
of binding site
Optimization
of enzyme
inhibitor
candidates
Virtual
screening and
selection of
enzyme
inhibitor
Molecular dynamics, SAR,
molecular modeling, QSAR,
modeling of pharmacophore
Docking
studies
10 234
Figure 14.3 Process involved in computer-aided design.
317
interest must exist for a ligand-based strategy to succeed. These substances, which can be patented
structures, comprehensive inhibitors, natural substrates, or even explored leads, are crucial for the
screening procedure since they operate as the foundational paradigms for the search.
14.4.4.2 Receptor Based
Receptor-based approaches embrace a distinct outlook by emphasizing the connection of the
ligand and the receptor rather than just the ligand itself. The main prerequisite for a receptor-based
VS is the availability of a three-dimensional target structure. Such a structure may be an NMR
structure, a crystallographic X-ray structure, or even a homology modeling structure [31]
(Figure 14.5).
Enzyme targets and fragments selected
from libraries
Thermal shifting on the basis of
fluoroscence
NMR spectroscopy, isothermal
titration spectroscopy, and X-ray
crystallography
Docking
Synthesis and
design
Validation and
optimization
Screening and
fragments hit
Competitive,
quantitative,
and binding
studies
First line
screening
Figure 14.4 Fragment-based design.
Target
(selection, structure, druggability,
state of protonation, flexibility of
molecules, and interaction with
water molecule)
Compound
libraries
Filter
Virtual hit
molecule
Protocol of docking
Post-filter
Figure 14.5 Phases of virtual screening method.
318
14.4.5 Natural Product-Based Discovery
Natural products are frequently touted for having an affluent framework that enables them to
function as ligands for an extensive range of enzymes and receptors. The fact that natural com-
pounds can work well as enzyme inhibitors can be attributed to a connection. Although natural
products have a lot of prospects for drug discovery, there are still several issues that can impede
the advancement of the pharmaceutical industry. Extracting natural products from living things
is the first hurdle in the procedure [32]. The chemical classes present in the extract depend on
the manner of extraction adopted. More polar solvents would boost the quantity of polar com-
pounds in the crude extract. The biological component can be extracted using countless solvents
with different polarities to elevate the variety of the retrieved natural products. The next step is
incremental bioactivity-guided fractionation until the pure bioactive components are separated
following the detection of a crude extract with promising pharmacological activity [33]
(Figure 14.6).
14.4.6 Using Iterative Protein Crystallographic Analysis
The study of proteins’ three-dimensional, atomically precise structures is recognized as protein
crystallography. Over the past few decades, it has shed a great deal of light on how many different
biological systems function. Over the past 10 years, the area has had a tremendous global boost in
both pharmaceutical and university laboratories [34]. The fundamental impetus behind this
expansion has been the hope that leads like enzyme inhibitors can be generated and existing medi-
cations’ effects can be enhanced by using the three-dimensional atomic structures of proteins and
other macromolecules. Understanding the complex nuances of protein structures has been essen-
tial for our comprehension of an array of biological activities, from enzymatic reactions to virus
immune circumvention. Enzyme structures have supplied information about the interactions of
substrates and inhibitors and the mechanism of enzyme-catalyzed reactions [35].
14.4.7 Utilization of Covalent Inhibitors
In drug discovery and treatment, covalent inhibitors are widely acknowledged as being crucial. In
general, molecules that evolve a covalent link with a particular molecular target qualify as covalent
inhibitors. Depending on the intended warhead, the covalent bond might be either reversible or
irreversible. Cysteine, serine, threonine, tyrosine, and lysine are just a few of the individual amino
acid residues that have been the target of various warheads [36].
Living organisms
Crude extract
Single entity
Fractionation
and evaluation of
bioactivity
Figure 14.6 Natural product-based discovery.
319
By forging specific interactions between the ligand and the target protein, covalent medicines
impair the normal functioning of proteins. Compared to a reversible mode of action, a covalent
mechanism of action can offer multiple states pharmacological benefits, such as improved effec-
tiveness, selectivity, and sustained duration of action. Many of the covalent medications that have
been approved ended up being discovered by chance. The emergence of a new class of covalent
medications known as “targeted covalent inhibitors” has been made foreseeable by computer-
assisted drug design [37].
14.4.8 Encapsulation Techniques
Enzyme recycling and deterioration under harsh circumstances can be minimized by encasing the
enzyme in a particulate nano- or microstructure. The size and chemoselectivity of the catalyzed
reaction are altered by the small reaction space. Surface effects may boost the reaction rate, and
elevating the local concentration of intermediates in a multicomponent reaction can maximize the
efficiency of the reaction [38, 39]. Therefore, unlike an enzyme in solution, one that is encapsu-
lated is frequently a better mimic of nature. The simple recovery for catalysis applications or
greater resilience to harmful conditions for usage in biotechnology and medicine are just a couple
of the many useful benefits of enzyme encapsulation [40].
Different matrix materials and various methods, such as physical entrapment, adsorption
through noncovalent interactions, and covalent attachment to the matrix, can be used to encap-
sulate enzymes. Proteins that naturally form casings are used in protein-based enzyme encap-
sulation [41]. Capsid proteins from both viral and nonviral organisms have been used for this.
The multimeric protein assemblies that make up viral capsids, also known as virus-like parti-
cles, have a high copy number and generate hollow shells with an elevated degree of
rigidity [42].
14.4.9 Based on Active-Site Specificity
When substrate molecules adhere to an enzyme, a chemical reaction ensues. This area is known as
the active site. The binding site, or amino acid residues, and the catalytic site, or amino acid resi-
dues, constitute the active site. The binding site initiates transient bonds with the substrate. High
specificity is accomplished by each active site being developed to be best suited to bind a specific
substrate and catalyze a specific reaction. The assembly of amino acids within the active site and
the makeup of the substrates both impact this selectivity. To execute their job, enzymes occasion-
ally need to bind with some cofactors [43].
Noncovalent linkages draw inhibitors and substrates to the active site. As a result, new mole-
cules that resemble the substrates are created. It has a group that can chemically react with a
protein’s amino acid residue. The compound’s characteristics that resemble a substrate would
help it find the active site, and the reactive group would then create a covalent bond that would
bind the inhibitor to the site [44]. The enzyme would subsequently become irreversibly inactive
as the irreversible complex would stop any further catalytic activity. Since then, active sites of
pure proteins and enzymes have been studied using active-site-directed labeling. Understanding
chemical modification strategies of enzyme specificity is necessary for the rational design of
site-directed enzymes. Knowing the components of the substrates that are not necessary for
binding is vital when designing an inhibitor so that their positions can be used to introduce a
possible connecting group. It may be possible to add linking groups at certain sites using the
enzyme’s tolerance to bulky substituents at specific positions of the substrate. In addition, it is
320
crucial to create a chemical for chemotherapy that will only interact with one of the numerous
comparable enzymes [45].
14.4.10 Machine Learning Inhibitor Design
The practice of generating new biocatalysts leveraging machine learning has gained prominence in
recent years. This approach is data-driven, as opposed to model-driven rational design, where it
seeks patterns in the current data to project the traits of a forthcoming input that has not been seen
before but is similar. ML-based design can generate new, previously undetected but promising varia-
tions based on the patterns in the acquired data, as opposed to directed evolution which periodically
selects the current mutants. ML is used in tandem with rational design and directed evolution [46].
The main goal of the majority of ML algorithms is to identify patterns in the provided data. These
data often comprise data points with many attributes or descriptors, such as amino acid changes,
enzyme secondary and tertiary structures, and sequences. Typically, there are hundreds to thou-
sands of characteristics, making the problem high-dimensional. Unsupervised, supervised, and
semi-supervised learning are the three main types of machine learning. In supervised learning, one
or more target attributes, such as enzyme activity or stability, are identified as labels. The objective is
to create a predictor that, utilizing a labeled training data set, would return labels for unseen data
points based on their descriptors. Semi-supervised learning is the combination of these two super-
vised and unsupervised ML types, which happens frequently. The following are the various steps[47]:
● The data are typically transformed into tables and divided into training and test portions. The
performance of the predictor will be impacted by any errors, biases, or imbalances; thus, they
must be taken into consideration.
● Using the training data set, the predictor is trained.
● Using the test data set as a basis, the predictor’s performance is assessed.
14.4.11 Enzyme-Templated Dynamic Combinatorial Chemistry
A new method for effectively finding novel chemical compounds that will attach to a specific
enzyme is called enzyme-directed dynamic combinatorial chemistry. To create a combinatorial
library, this method typically uses a library of tiny molecules that interact reversibly with one
another. The combinatorial library’s elements are in thermodynamic equilibrium with one
another. When an enzyme is added to the equilibrium mixture, the equilibrium position will
shift and any combinatorial library components that interact with the protein will be amplified.
These components can then be identified by a suitable biophysical technique. This knowledge
can serve as a springboard for further chemical synthesis of inventive protein ligands and enzyme
inhibitors [48].
The basic building blocks of a protein-compatible combinatorial library typically consist of a
variety of tiny and simple compounds that may interact with one another reversibly in aqueous
solution and at physiologically relevant pH. They are frequently referred to as “building blocks”
for systems. Under thermodynamic control, all of these small molecule building blocks and their
reaction products are in equilibrium with one another in the mixture. Their relative distribution
in the mixture indicates each component’s thermodynamic stability within the equilibrium.
Essentially, any enzyme-directed experiment should include four elements: a protein blueprint,
an archive of components, a reversible reaction, and analytical methods [49] (Figure 14.7).
14.6 uture Directions 321
14.5 Limitations and Challenges
Nevertheless, there are hurdles in generating enzyme inhibitors. Achieving selectivity is a massive
challenge. For off-target effects to be kept to a minimum and treatment efficacy to be improved,
inhibitors must be assured to target the desired enzyme selectively while not impacting other
important proteins or enzymes. Understanding an enzyme’s structure, activity, and specificity in
depth is frequently crucial for accomplishing selectivity. The fabrication of enzyme inhibitors must
also overcome drug resistance. The effectiveness of inhibitors can be diminished through the
emergence of mechanisms by illnesses or enzymes to circumvent inhibition. The development of
inhibitors that circumvent or bypass the aforementioned resistance pathways is what researchers
must do to anticipate and combat these resistance mechanisms [50]. Combination treatment,
which combines the use of many enzyme inhibitors or inhibitors with other therapeutic methods,
can also aid in minimizing medication resistance. In the design of enzyme inhibitors, pharmacoki-
netic issues frequently arise. To guarantee efficient transport and action at the target location, it is
essential to optimize the inhibitors’ drug-like qualities, such as bioavailability, stability, and metab-
olism. To enhance pharmacological characteristics while preserving the desired inhibitory effect,
substantial medicinal chemistry efforts are frequently required [51].
Several strategies can be used to deal with these problems. Designing inhibitors with increased
selectivity and potency benefits from rational drug development, which makes use of structural
data and computational modeling. Potential inhibitors that can be further optimized for desired
qualities can be found by high-throughput screening of vast chemical libraries. An effective
technique to investigate the chemical realm and find potential areas for inhibitor development
is through fragment-based lead generation [52]. The efficacy of enzyme inhibitors may also be
boosted by using combination therapy and personalized medicine strategies. To target particular
enzymes and thwart disease processes, enzyme inhibitors are designed strategically for medica-
tion development. However, aspects including accomplishing selectivity, managing resistance,
and strengthening pharmacokinetic traits must be tackled. Researchers may generate efficient
enzyme inhibitors with great therapeutic potential for a variety of diseases by combining several
techniques and continuously improving our understanding of enzyme function [53].
14.6 Future Directions
The capacity to target enzymes participating in numerous pathways as well as the creation of more
strong and selective inhibitors are key to the future of enzyme inhibitor-based medication discov-
ery. The use of enzyme inhibitors in conjunction with other therapeutic approaches, such as gene
Figure 14.7 Enzyme-templated dynamic combinatorial chemistry.
322
therapy, also has a lot of potential. And finally, one of the most intriguing areas of research is the
creation of revolutionary computational techniques for the design and enhancement of medica-
tions based on enzyme inhibitors. Through the use of such techniques, it may be possible to find
novel inhibitors that are even more potent than those that are already known, which would speed
up the creation of more effective medicines for several diseases [54].
14.7 Conclusion
A crucial component of drug discovery and development is the design of enzyme inhibitors. The
activity of particular enzymes implicated in disease processes is modulated by enzyme inhibitors,
which provide focused therapeutic interventions. To find and improve potential inhibitors, tech-
niques including structure-based drug design, ligand-based drug design, and fragment-based drug
design are helpful. Enzyme inhibitor design does, however, provide several formidable difficulties.
Selectivity is a key goal that must be attained to guarantee that inhibitors only affect the desired
enzyme and leave off-target proteins unaffected. Innovative methods and combination therapies
are needed to combat medication resistance, which occurs when illnesses or enzymes discover
ways to circumvent inhibition. For the inhibitors to be delivered and used effectively, it is also
crucial to optimize their pharmacokinetic qualities. To overcome these difficulties, researchers
develop inhibitors with increased selectivity, potency, and drug-like features using rational drug
design, high-throughput screening, fragment-based lead generation, and other techniques.
Processes for designing and optimizing inhibitors could be sped up with the integration of com-
puter techniques like artificial intelligence and machine learning. Exploring new target classes and
newly discovered enzyme families for therapeutic intervention is where the future of enzyme
inhibitor creation lies. Precision targeting and advances in personalized therapy provide consider-
able promise for improved efficacy and fewer adverse effects by customizing inhibitors to specific
patients or disease subtypes. In general, effective medication development depends on an aware-
ness of the approaches and difficulties in enzyme inhibitor design. Researchers can overcome
obstacles and create highly potent and selective enzyme inhibitors for a variety of diseases by uti-
lizing novel approaches and continually expanding our knowledge of enzyme biology. By doing so,
they can significantly advance the field of drug design and improve patient outcomes.
References
1 Hopkins, A.L. and Groom, C.R. (2002). The druggable genome. Nature Reviews. Drug Discovery 1:
727–730. https://doi.org/10.1038/nrd892.
2 Consalvi, S., Biava, M., and Poce, G. (2015). COX inhibitors: a patent review (2011–2014). Expert
Opinion on Therapeutic Patents 25: 1357–1371. https://doi.org/10.1517/13543776.2015.1090973.
3 Ng, H.L., Chen, S.Y., Chew, E.H., and Chui, W.K. (2016). Applying the designed multiple ligands
approach to inhibit dihydrofolate reductase and thioredoxin reductase for antiproliferative activity.
European Journal of Medicinal Chemistry 115: 63–74. https://doi.org/10.1016/j.ejmech.2016.03.002.
4 Nikolic, K., Mavridis, L., Djikic, T. et al. (2016). Drug design for CNS diseases: polypharmacological
profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies.
Frontiers in Neuroscience 10. https://doi.org/10.3389/fnins.2016.00265.
5 Hughes, R.E., Nikolic, K., and Ramsay, R.R. (2016). One for all? Hitting multiple Alzheimer’s
disease targets with one drug. Frontiers in Neuroscience 10. https://doi.org/10.3389/fnins.2016.00177.